Advances in recombinant adeno-associated viral vectors for gene delivery

Current Gene Therapy

Volumn 13, Issue 5, 2013, Pages 335-345

  Petrs Silva, Hilda ^a   Linden, Rafael ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adeno associated virus; Directed evolution; Efficacy; Gene transfer; Safety; Selective mutagenesis; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ADJUVANT; BORTEZOMIB; DYSTROPHIN; GENISTEIN; LUTEINIZING HORMONE; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; VIRUS HEMAGGLUTININ;

ARTICLE; DNA PACKAGING; GENE; GENE EXPRESSION; GENE THERAPY; HUMAN; MUTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RPE65 GENE; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS CAPSID; VIRUS GENOME;

AMINO ACID SEQUENCE; ANIMALS; CAPSID PROTEINS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS;

EID: 84890755202     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/15665232113136660028     Document Type: Article

References (86)

1. Tatum EL. Molecular biology, nucleic acids, and the future of medicine. Perspect Biol Med 1966; 10(1):19-32.
2. Neufeld EF, Sweeley CC, Rogers S, Friedmann T, Roblin R. Gene therapy for human genetic disease? Science 1972; 178(4061):648-9.
3. Wigler M, Silverstein S, Lee LS, Pellicer A, Cheng Y, Axel R. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 1977; 11(1):223-32.
4. Joyner A, Keller G, Phillips RA, Bernstein A. Retrovirus transfer of a bacterial gene into mouse haematopoietic progenitor cells. Nature 1983; 305(5934):556-8.
5. Miller AD, Jolly DJ, Friedmann T, Verma IM. A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT. Proc Natl Acad Sci U S A 1983; 80(15):4709-13.
6. Cotrim AP, Baum BJ. Gene therapy: some history, applications, problems, and prospects. Toxicol Pathol 2008; 36(1):97-103.
7. High KA. The gene therapy journey for hemophilia: are we there yet? Blood 2012; 120(23):4482-7.
8. Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J 2009; 11(4):671-81.
9. Giacca M, Zacchigna S. Virus-mediated gene delivery for human gene therapy. J Control Release 2012; 161(2):377-88.
10. Herzog RW, Cao O, Srivastava A. Two decades of clinical gene therapy--success is finally mounting. Discov Med 2010; 9(45):105-11.
11. Culver KW, Anderson WF, Blaese RM. Lymphocyte gene therapy. Hum Gene Ther 1991; 2(2):107-9.
12. Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003; 101(7):2563-9.
13. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80(1-2):148-58.
14. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288(5466):669-72.
15. Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 2007; 117(6):1456-65.
16. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A 2013; 110(6):E517-25.
17. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008; 15(11):858-63.
18. Lorenz B, Preising M, Stieger K. Retinal blinding disorders and gene therapy - molecular and clinical aspects. Curr Gene Ther 2010; 10(5):350-70.
19. Colella P, Auricchio A. AAV-mediated gene supply for treatment of degenerative and neovascular retinal diseases. Curr Gene Ther 2010; 10(5):371-80.
20. Grieger JC, Samulski RJ. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol 2012; 507:229-54.
21. Kerr JR, Linden RM. Human dependovirus infection. In: J.R. K, Cotmore SF, Bloom ME, Linden RM, Parrish CR, eds. Parvoviruses. London: Hodder Arnold 2006:381-5.
22. Agbandje-McKenna M, Kleinschmidt J. AAV capsid structure and cell interactions. Methods Mol Biol 2011; 807:47-92.
23. Gao G, Zhou X, Alvira MR, et al. High throughput creation of recombinant adenovirus vectors by direct cloning, green-white selection and I-Sce I-mediated rescue of circular adenovirus plasmids in 293 cells. Gene Ther 2003; 10(22):1926-30.
24. Vandenberghe LH, Wilson JM, Gao G. Tailoring the AAV vector capsid for gene therapy. Gene Ther 2009; 16(3):311-9.
25. Deyle DR, Russell DW. Adeno-associated virus vector integration. Curr Opin Mol Ther 2009;11(4):442-7.
26. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007; 317(5837):477.
27. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5(3):285-97.
28. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adenoassociated virus (AAV-2), a vector for Human Gene Therapy. Proc Natl Acad Sci U S A 2002; 99(16):10405-10.
29. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992; 158:97-129.
30. Govindasamy L, Padron E, McKenna R, et al. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol 2006; 80(23):11556-70.
31. Hauck B, Chen L, Xiao W. Generation and characterization of chimeric recombinant AAV vectors. Mol Ther 2003; 7(3):419-25.
32. Bowles DE, Rabinowitz JE, Samulski RJ. Marker rescue of adenoassociated virus (AAV) capsid mutants: a novel approach for chimeric AAV production. J Virol 2003; 77(1):423-32.
33. Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SE, Samulski RJ. Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol 2004; 78(9):4421-32.
34. Asokan A, Conway JC, Phillips JL, et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 2010; 28(1):79-82.
35. Walters RW, Agbandje-McKenna M, Bowman VD, et al. Structure of adeno-associated virus serotype 5. J Virol 2004; 78(7):3361-71.
36. DiMattia M, Govindasamy L, Levy HC, et al. Production, purification, crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 5. Acta Crystallogr Sect F Struct Biol Cryst Commun 2005; 61(Pt 10):917-21.
37. Padron E, Bowman V, Kaludov N, Govindasamy L, Levy H, Nick P, et al. Structure of adeno-associated virus type 4. J Virol 2005; 79(8):5047-58.
38. Lane MD, Nam HJ, Padron E, et al. Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8. Acta Crystallogr Sect F Struct Biol Cryst Commun 2005; 61(Pt 6):558-61.
39. Mitchell M, Nam HJ, Carter A, et al. Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 9. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009; 65(Pt 7):715-8.
40. Becerra SP, Koczot F, Fabisch P, Rose JA. Synthesis of adenoassociated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J Virol 1988; 62(8):2745-54.
41. Hermonat PL, Labow MA, Wright R, Berns KI, Muzyczka N. Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol 1984; 51(2):329-39.
42. Tratschin JD, Miller IL, Carter BJ. Genetic analysis of adenoassociated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol 1984; 51(3):611-9.
43. Wu P, Xiao W, Conlon T, et al. Mutational analysis of the adenoassociated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000; 74(18):8635-47.
44. Warrington KH, Jr., Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol 2004; 78(12):6595-609.
45. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3(6):964-75.
46. Shi W, Bartlett JS. RGD inclusion in VP3 provides adenoassociated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 2003; 7(4):515-25.
47. Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 2001; 12(14):1697-711.
48. Loiler SA, Conlon TJ, Song S, et al. Targeting recombinant adenoassociated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther 2003; 10(18):1551-8.
49. Liu Y, Fang Y, Zhou Y, et al. Site-specific modification of adenoassociated viruses via a genetically engineered aldehyde tag. Small 2013; 9(3):421-9.
50. Perabo L, Goldnau D, White K, et al. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol 2006; 80(14):7265-9.
51. Michelfelder S, Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv genet 2009;67:29-60.
52. Huttner NA, Girod A, Perabo L, et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther 2003; 10(26):2139-47.
53. Lochrie MA, Tatsuno GP, Christie B, et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol 2006; 80(2):821-34.
54. Bornscheuer UT, Huisman GW, Kazlauskas RJ, Lutz S, Moore JC, Robins K. Engineering the third wave of biocatalysis. Nature 2012; 485(7397):185-94.
55. Traxlmayr MW, Obinger C. Directed evolution of proteins for increased stability and expression using yeast display. Arch Biochem Biophy 2012; 526(2):174-80.
56. Glauser DL, Ackermann M, Saydam O, Fraefel C. Chimeric herpes simplex virus/adeno-associated virus amplicon vectors. Curr Gene Ther 2006; 6(3):315-24.
57. Schaffer DV, Maheshri N. Directed evolution of AAV mutants for enhanced gene delivery. Conf Proc IEEE Eng Med Biol Soc 2004; 5:3520-3.
58. Koerber JT, Klimczak R, Jang JH, Dalkara D, Flannery JG, Schaffer DV. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 2009; 17(12):2088-95.
59. Excoffon KJ, Koerber JT, Dickey DD, et al. Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc Natl Acad Sci U S A 2009; 106(10):3865-70.
60. Grimm D, Lee JS, Wang L, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008; 82(12):5887-911.
61. Asuri P, Bartel MA, Vazin T, Jang JH, Wong TB, Schaffer DV. Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther 2012; 20(2):329-38.
62. Yang L, Xiao X. Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution. Virol J 2013; 10:50.
63. Maersch S, Huber A, Buning H, Hallek M, Perabo L. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology 2010; 397(1):167-75.
64. Ortolano S, Spuch C, Navarro C. Present and future of adeno associated virus based gene therapy approaches. Recent Pat Endocr Metab Immune Drug Discov 2012;6(1):47-66.
65. Timpe J, Bevington J, Casper J, Dignam JD, Trempe JP. Mechanisms of adeno-associated virus genome encapsidation. Curr Gene Ther 2005; 5(3):273-84.
66. Musatov SA, Scully TA, Dudus L, Fisher KJ. Induction of circular episomes during rescue and replication of adeno-associated virus in experimental models of virus latency. Virology 2000; 275(2):411-32.
67. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008; 16(10):1648-56.
68. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10(26):2105-11.
69. Miao CH, Nakai H, Thompson AR, et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol 2000; 74(8):3793-803.
70. Zhong L, Zhao W, Wu J, et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007; 15(7):1323-30.
71. Goater J, Muller R, Kollias G, et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol 2000; 27(4):983-9.
72. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci U S A 1995; 92(12):5719-23.
73. Denby L, Nicklin SA, Baker AH. Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Ther 2005; 12(20):1534-8.
74. Zhang FL, Jia SQ, Zheng SP, Ding W. Celastrol enhances AAV1- mediated gene expression in mice adipose tissues. Gene Ther 2011; 18(2):128-34.
75. Hacker UT, Wingenfeld L, Kofler DM, et al. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J Gene Med 2005; 7(11):1429-38.
76. Zhong L, Li B, Jayandharan G, et al. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 2008; 381(2):194-202.
77. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105(11):1573-87.
78. Yan Z, Zak R, Luxton GW, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 2002; 76(5):2043-53.
79. Li W, Zhang L, Wu Z, Pickles RJ, Samulski RJ. AAV-6 mediated efficient transduction of mouse lower airways. Virology 2011; 417(2):327-33.
80. Petrs-Silva H, Dinculescu A, Li Q, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009; 17(3):463-71.
81. Petrs-Silva H, Dinculescu A, Li Q, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19(2):293-301.
82. Qi YF, Li QH, Shenoy V, et al. Comparison of the transduction efficiency of tyrosine-mutant adeno-associated virus serotype vectors in kidney. Clin Exp Pharmacol Physiol 2013; 40(1):53-5.
83. Dalkara D, Byrne LC, Lee T, Hoffmann NV, Schaffer DV, Flannery JG. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther 2012; 19(2):176-81.
84. Qiao C, Yuan Z, Li J, Tang R, Li J, Xiao X. Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. Hum Gene Ther Methods 2012; 23(1):29-37.
85. Qiao C, Zhang W, Yuan Z, et al. Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 2010; 21(10):1343-8.
86. Ussher JE, Taylor JA. Optimized transduction of human monocytederived dendritic cells by recombinant adeno-associated virus serotype 6. Hum Gene Ther 2010; 21(12):1675-86.